Harrow is a fast-growing ophthalmic pharma company focused on delivering eye care drugs. Click here to read more about HROW's ...

Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...

Harrow Health, an eye care pharmaceutical company, announced Wednesday morning that Novartis agreed to sell five drugs approved by the Food and Drug Administration for up to $175 million. Harrow will ...

Eyecare pharmaceutical company Harrow Health is expanding its Nashville corporate headquarters in a $3 million investment that is slated to bring 147 new jobs to the city. Harrow announced the move ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Energy Transfer LP (NYSE:ET). “The pipes are a great business here, they really are,” he added. On the earnings front, Energy ...